Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glaxo Seeks Indian Consumer Growth, Expanded Capacity

This article was originally published in The Tan Sheet

Executive Summary

GSK hopes to grow in all three of its business areas – consumer healthcare, pharmaceuticals and vaccines – in India with product introductions and a strategy to expand further into rural markets. CEO Andrew Witty previously headed Glaxo’s Asia Pacific operations and says he is a “huge bull on India.”

You may also be interested in...

Glaxo Keeps Alli As Recently Pruned Consumer Division Thrives

GlaxoSmithKline abandons its attempt to divest the OTC weight loss aid alli, even though the beleaguered brand continues to drag down consumer division sales. The division’s sales climbed 7% excluding alli in the firm’s second quarter, but only 5% including the product’s results.

Need For A Vaccines Unit In India Pushes GSK Closer To Align With India's Biological E; Is A Buyout Imminent ?

MUMBAI - GlaxoSmithKline Plc.'s vaccines arm, the Belgium-headquartered GSK Biologicals S.A. is believed to be on course to acquire Hyderabad, India-based vaccines manufacturer Biological E. Ltd., a report in The Economic Times said last week. If the deal comes to fruition, GSK would fulfil its long desire to buy an Indian asset that could be leveraged for its expanding network in the high potential emerging markets

GSK India Managing Director Hasit Joshipura On Business Dynamics In India, Tiered Pricing And Approaches To Rural Markets: An Interview With PharmAsia News (Part 2 Of 2)

Hasit Joshipura, GlaxoSmithKline's India Managing Director is unfazed by the recent mega-deal that Abbott struck with Piramal Healthcare - catapulting the U.S. giant to the number one slot in India with a market share of nearly 7 percent.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts